Home PACS News PACS Corporate News National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain
National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain PDF Print E-mail
Written by PACSMule Administrator   
Friday, 22 January 2016 17:00
Gadolinium-based contrast agents (GBCAs) are currently approved by the FDA for use in conjunction with MRI. GBCAs are indispensable adjuncts to MRI, with numerous studies showing their efficacy in improving the accuracy of MRI studies, and they have a positive cumulative safety record to date. For example, acute adverse reactions have been reported in only approximately 0.079% of all administrations, of which 91% were classified as mild reactions [1]. Despite the positive safety profile immediately after the injection of GBCAs, there has been recent attention to reports of gadolinium deposition in the brains of patients who received multiple doses of GBCAs [2-6].

Read more